D
Xenetic Biosciences, Inc. XBIO
$2.59 -$0.08-3.00%
Recommendation
Sell
Prev Close
$2.67
Volume
3,098
Avg Vol (90D)
10,867
Market Cap
$4.12M
Dividend & Yield
--
52-Week Range
$2.26 - $5.20
P/E (TTM)
--
EPS (TTM)
-$2.57
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
3/26/2025 - Accesswire
HC Wainwright Reaffirms Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO)
3/20/2025 - Ticker Report
Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
3/20/2025 - Simply Wall St
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
3/19/2025 - GuruFocus
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
3/19/2025 - Accesswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of ...
3/13/2025 - GuruFocus
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
3/13/2025 - Accesswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society ...
2/27/2025 - GuruFocus
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
2/27/2025 - Accesswire
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Growth in Short Interest
1/30/2025 - Ticker Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
12/17/2024 - GuruFocus
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
12/17/2024 - Accesswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the ...
12/16/2024 - GuruFocus
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
12/16/2024 - Accesswire
HC Wainwright Reiterates and#8220;Neutral" Rating for Xenetic Biosciences (NASDAQ:XBIO)
12/7/2024 - Ticker Report
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. ...
12/5/2024 - GuruFocus
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
12/5/2024 - Accesswire
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Declines By 43.2%
11/30/2024 - Ticker Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
11/22/2024 - GuruFocus
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
11/22/2024 - Accesswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of ...
11/21/2024 - GuruFocus
H.C. Wainwright Sticks to Their Hold Rating for Xenetic Biosciences (XBIO)
11/21/2024 - TipRanks Financial Blog
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
11/21/2024 - Accesswire
Xenetic Biosciences GAAP EPS of -$0.28, revenue of $614.1M
11/13/2024 - SeekingAlpha.com: All News
Income Statement
Total Revenue (TTM)
$2.50M
EBITDA (TTM)
--
EBIT (TTM)
-$4.20M
Net Income (TTM)
-$3.96M
Balance Sheet
Total Assets (Q)
$6.90M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$894.30K
Book Value Per Share (Q)
$3.89
Cash Flow
Cash from Operations (TTM)
-$2.82M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
-$2.82M
Filings
Filing Date
Tuesday, March 18, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.10
7-Day Total Return
-23.37%
30-Day Total Return
-35.73%
60-Day Total Return
-40.05%
90-Day Total Return
-35.09%
Year to Date Total Return
-36.05%
1-Year Total Return
-43.94%
2-Year Total Return
-36.83%
3-Year Total Return
-76.24%
5-Year Total Return
-65.37%
52-week Low
Apr 02, 2025 - $2.26
52-week High
Aug 05, 2024 - $5.20
Valuation
Market Cap
$4.12M - Nano Cap
Enterprise Value
-$2.05M
Price/Sales (TTM)
1.65
Price/Book (Q)
0.69
Dividends and Shares
Shares Outstanding
1.54M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.xeneticbio.com
Phone Number
781 778 7720
Address
945 Concord Street
Framingham, MA 01701
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to... more
NASDAQ 04/03/2025 3:22PM Eastern Quotes delayed
Weiss Ratings